Study finds current prostate cancer screening guidelines may miss early-stage cancers in transgender women on hormone therapy due to lowered PSA levels.
A new study by Cedars-Sinai Cancer investigators reveals that current prostate cancer screening guidelines may miss early-stage cancers in transgender women on hormone therapy. Estrogen, often used in gender-affirming care, lowers PSA levels, potentially elevating the 'normal' threshold for detection. The study published in JAMA aims to determine typical PSA values for transgender women to improve screening methods.
June 26, 2024
3 Articles